Innovation Zed and A.Menarini Diagnostics Enter Commercial Agreement for International Distribution of Innovative Insulin Pen ‘InsulCheck Connect’ Device

Innovation Zed and A.Menarini Diagnostics Enter Commercial Agreement for International Distribution of Innovative Insulin Pen ‘InsulCheck Connect’ Device

Innovation Zed Ltd, an Irish medical technology company, and A.Menarini Diagnostics, a leading diagnostics company headquartered in Italy, and part of the Menarini Group, today announced an international partnership to commercialise the ‘InsulCheck Connect’ device developed by Innovation Zed.

‘InsulCheck Connect’ is an innovative insulin pen add-on device. It automatically collects essential usage data that informs insulin pen users of their injection history to assist them take control of their diabetes management. The ‘InsulCheck Connect’ device was specifically chosen to integrate within A.Menarini Diagnostics’ connected diabetes care platform.

With this agreement the two companies are forming a long-term partnership where A.Menarini Diagnostics will perform sales, marketing, training, and customer support, providing all necessary technical and clinical information for the correct use of the Insulin Pen ‘InsulCheck Connect’ device in regions around the globe including Europe.

Innovation Zed is headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin (UCD).

“We are very pleased with this announcement,” said, Dean Minnock, Director of Business Development and Third-Party Relationships, Innovation Zed.

“The relationships that A.Menarini Diagnostics has established with patients and healthcare providers in the diabetes community, and their extensive distribution expertise will positively position us to deliver to key international markets.”

“With this innovative insulin pen ‘InsulCheck Connect’ device, healthcare providers and patients will have a powerful tool to take under control the blood glucose levels and prevent diabetes complications,” said Fabio Piazzalunga, General Manager and Global Head, A.Menarini Diagnostics.

“This agreement is part of our strategy to develop a portfolio of fully integrated innovative products, allowing an enhanced management of diabetes for healthcare providers and an improved quality of life for patients.”

Dean Minnock, added, “A.Menarini Diagnostics has established fantastic relationships with patients and healthcare providers and has extensive distribution expertise to effectively utilise the ‘InsulCheck Connect’ device to greatly empower the diabetes community."

A.Menarini Diagnostics and Innovation Zed are also discussing terms to commercialise additional innovative systems to improve the quality of life for patients with diabetes.

ENDS

28 January 2020

For further information contact Micéal Whelan, Communications and Media Relations Manager, NovaUCD, UCD Research and Innovation, e: miceal.whelan@ucd.ie or t: +353 1 716 3712 or Dean Minnock, Director of Business Development and Third-Party Relationships, Innovation Zed, e: deanm@insulcheck.com.

Editors Notes

Innovation Zed Ltd is a medical technology company from Ireland, specialising connected health solutions that enable a step-up in user engagement, condition management and improved drug adherence for all injectable therapies. www.innovationzed.com

Menarini Diagnostics, the Human Touch of Technology: more than 35 years dedicated to helping healthcare professionals make safe and sustainable diagnoses, meeting and exceeding the technological needs of Europe's most prominent healthcare professionals, improving and enhancing the quality of life of people with diabetes all over the world. A.Menarini Diagnostics belongs to the Menarini Pharmaceutical Group which was founded in 1886. Today with presence in 136 countries throughout the world, it counts more than 17.000 employees and has a 2018 turnover of €3.667 billion. www.menarinidiagnostics.com